Cladribine

Drug Profile

Cladribine

Alternative Names: 2-CdA; 2-Chloro-2-deoxyadenosine; 2-Chlorodeoxyadenosine; 2CDA; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Leustatine; Mavenclad; Movectro; Mylinax; N-l-Leucyl-doxorubicin; RWJ 26251

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Scripps Clinic
  • Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
  • Class Antineoplastics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Immunosuppressants; Purinergic P1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis; Leukaemia; Lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 27 Jun 2017 Pharmacodynamics data from pooled analysis of phase III trials CLARITY, CLARITY Extension and ORACLE-MS in Multiple sclerosis presented at the 3rd Congress of the European Association of Neurology (EAN-2017)
  • 23 Jun 2017 The CHMP recommends approval of cladribine for Multiple sclerosis in European Union
  • 28 Apr 2017 Efficacy data from the retrospective subgroup analysis of phase III CLARITY trial in Multiple sclerosis presented at the the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top